Table 2.
Subject characteristics by molecular imaging classification
| AD (n = 47) | DLB (n = 15) | FTD (n = 13) | P | |
|---|---|---|---|---|
| Demographics | ||||
| Age | 71 ± 9 | 75 ± 6 | 69 ± 9 | 0.089 |
| Female, n (%) | 23 (49) | 4 (27) | 3 (23) | 0.121 |
| White, n (%) | 45 (96) | 13 (87) | 13 (100) | 0.293 |
| Years of education | 15 ± 3 | 15 ± 3 | 15 ± 3 | 0.957 |
| CDR | 1.0 ± 0.5 | 1.1 ± 0.8 | 0.8 ± 0.4 | 0.424 |
| MMSE | 22 ± 4 | 23 ± 4 | 23 ± 3 | 0.146 |
| APOE4 heterozygote, n (%) | 13 (28) | 5 (33) | 3 (23) | 0.831 |
| APOE4 homozygote, n (%) | 10 (21) | 1 (7) | 0 (0) | 0.098 |
| Historical features, n (%) | ||||
| Memory complaint | 39 (83) | 12 (80) | 11 (85) | 0.945 |
| Behavioural complaint | 5 (11) | 3 (20) | 8 (62) | <0.001 |
| Parkinsonism | 5 (11) | 8 (53) | 2 (15) | 0.001 |
| Hallucinations | 1 (2) | 6 (40) | 2 (15) | <0.001 |
| Neuropsychological indices | ||||
| Logical Memory | 5.7 ± 4.5 | 8.3 ± 4.0 | 8.4 ± 4.5 | 0.040 |
| Digit span forward | 6.8 ± 2.3 | 7.2 ± 2.9 | 5.5 ± 2.1 | 0.108 |
| Digit span backwards | 4.2 ± 1.8 | 4.4 ± 2.2 | 4.2 ± 1.4 | 0.961 |
| Animals | 12 ± 5 | 9 ± 4 | 13 ± 5 | 0.121 |
| Trail Making Test, Part A | 107 ± 193 | 89 ± 44 | 134 ± 261 | 0.325 |
| Trail Making Test, Part B | 536 ± 389 | 568 ± 364 | 405 ± 345 | 0.332 |
| Block Design | 24 ± 13 | 21 ± 7 | 27 ± 10 | 0.280 |
| Logical Memory-Delayed Recall | 4.4 ± 4.0 | 6.5 ± 4.9 | 7.1 ± 4.0 | 0.050 |
| Boston Naming Test | 22 ± 6 | 24 ± 4 | 25 ± 3 | 0.255 |
| NPI-Q total score | 2.4 ± 2.2 | 2.5 ± 2.2 | 3.5 ± 2.7 | 0.325 |
| NPI-Q severity | 3.3 ± 3.7 | 4.1 ± 4.4 | 6.2 ± 5.1 | 0.163 |
Values represent the mean ± SD of demographic, clinical and neuropsychological characteristics, except where noted. AD = Alzheimer’s disease; CDR = clinical dementia rating scale score; DLB = dementia with Lewy bodies; FTD = frontotemporal dementia; MMSE = Folstein Mini-Mental Status Examination score; NPI-Q = Neuropsychiatric Inventory.
Bold values are significant at an unadjusted threshold of p < 0.05.